Skip to main content

Table 1 Included studies

From: Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice

Author Drug Indication Protocol Number of studies Adverse effects Study design “drug monitoring” included in search Information sources RoB/Quality assessment of studies Meta analysis
Cooney 2016 [8] Aminophylline Asthma No 12 Yes No restrictions No Medine, CINAHL, Cochrane Central, and Web of Science Cochrane tool for assessment of risk of bias [35], CASP tool [36] No
Sparshatt 2009 [10] Amisulpride Schizophrenia/schizoaffective disorder No 10 Yes No restrictions No Embase, Medline and PubMed None No
Sparshatt 2010 [14] Aripirazole No specific diagnosis No 8 No No restrictions Yes Embase, Medline, and PubMed None No
Knight 2008 [11] Mycophenolate Mofetil Transplant patients No 12 Yes RCTs, Observational studies No Medline, Embase, Cochrane Central, Transplant Library, Clinical trial registries None No
Zuk 2009 [15] Mycophenolate Mofetil Heart transplant No 7 No No restrictions Yes Medline Embase None No
Bishara 2013 [16] Olanzapine Schizophrenia/schizoaffective disorder/bipolar disorder No 30 Yes No restrictions Yes PubMed, Medline, Embase None Yes
Konidari 2014 [9] Thiopurine IBD No 15 Yes RCTs, Observational studies Yes PubMed, Medline, UK national health system database NICE defined criteria for quality assessment of case series [37] No
Moreau 2014 [17] Thiopurine IBD Yes 17 No No restrictions Yes Medline, Cochrane Library, DirectScience, and Google Scholar Nonea Yes
Osterman 2006 [12] Thiopurine IBD No 12 No No restrictions No Medline, PubMed Plus None Yes
Prybylski 2015 [13] Vancomycin S. aureus bacteraemia No 14 No Observational studies No PubMed None Yes
  1. RoB Risk Of bias, IBD Inflammatory Bowel Disease, RCT Randomised controlled trial, CENTRAL Central Register of Controlled Trials
  2. aMoreau et al. used the MOOSE consensus statement to assess reporting quality, but do not report the results of their assessment